PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK

6. S
7. ULTA
8. NVDA
9. GAP
10. DG

Get Alerts PYPD Hot Sheet

Price: $5.07 -0.98%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX100 in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.

The 2022 Military Health System Research Symposium:

Title:	D-PLEX100, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries.
Presenter:	Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer, PolyPid.
Date:	Monday, September 12, 2022

The abstract will be available on www.polypid.com/publications/ following the presentation.

About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995[email protected]

Investors:Bob YedidLifeSci Advisors646-597-6989[email protected]

Media Contact:Nechama Feuerstein551-444-0784[email protected]